A clinical stage biotechnology company developing best in class complement inhibitors for neuromuscular diseases.

Dianthus Therapeutics is a clinical-stage company focused on developing best in class complement inhibitors, a validated target. The lead product, DNTH103 is a YTE half-life extended antibody selective for the active form of C1s. This selective inhibition should allow for DNTH to treat many severe autoimmune and neuromuscular disorders such as myasthenia gravis, multifocal motor neuropathy and chronic inflammatory demyelinating polyneuropathy while providing a safer therapeutic option versus currently approved terminal complement pathway inhibitors.